﻿               SEQUENCE LISTING

<110> Charité - Universitätsmedizin Berlin

<120> A ratio between PlGF and sFLT-1 is predictive for neural invasion in patients suffering from pancreatic cancer

<130> P25453WO

<160> 10

<170> BiSSAP 1.3.6

<210> 1
<211> 8
<212> PRT
<213> Artificial Sequence


<220> 
<223> CDR1 heavy chain

<400> 1
Gly Tyr Thr Phe Thr Asp Tyr Tyr 
1               5               

<210> 2
<211> 8
<212> PRT
<213> Artificial Sequence


<220> 
<223> CDR2 heavy chain

<400> 2
Ile Tyr Pro Gly Ser Gly Asn Thr 
1               5               

<210> 3
<211> 9
<212> PRT
<213> Artificial Sequence


<220> 
<223> CDR3 heavy chain

<400> 3
Val Arg Asp Ser Pro Phe Phe Asp Tyr 
1               5                   

<210> 4
<211> 12
<212> PRT
<213> Artificial Sequence


<220> 
<223> CDR1 light chain

<400> 4
Gln Ser Leu Leu Asn Ser Gly Met Arg Lys Ser Phe 
1               5                   10          

<210> 5
<211> 4
<212> PRT
<213> Artificial Sequence


<220> 
<223> CDR2 light chain; wherein X can be any amino acid or absent

<400> 5
Trp Ala Ser Xaa 
1               

<210> 6
<211> 8
<212> PRT
<213> Artificial Sequence


<220> 
<223> CDR3 light chain

<400> 6
Lys Gln Ser Tyr His Leu Phe Thr 
1               5               

<210> 7
<211> 116
<212> PRT
<213> Artificial Sequence


<220> 
<223> heavy chain variable region

<400> 7
Gln Ile Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Ala 
1               5                   10                  15      
Ser Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Tyr 
            20                  25                  30          
Tyr Ile Asn Trp Val Lys Leu Lys Pro Gly Gln Gly Leu Glu Trp Ile 
        35                  40                  45              
Gly Trp Ile Tyr Pro Gly Ser Gly Asn Thr Lys Tyr Asn Glu Lys Phe 
    50                  55                  60                  
Lys Gly Lys Ala Thr Leu Thr Ile Asp Thr Ser Ser Ser Thr Ala Tyr 
65                  70                  75                  80  
Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Thr Ala Val Tyr Phe Cys 
                85                  90                  95      
Val Arg Asp Ser Pro Phe Phe Asp Tyr Trp Gly Gln Gly Thr Thr Leu 
            100                 105                 110         
Thr Val Ser Ser 
        115     

<210> 8
<211> 112
<212> PRT
<213> Artificial Sequence


<220> 
<223> light chain variable region

<400> 8
Asp Ile Val Leu Ser Gln Ser Pro Ser Ser Leu Ala Val Ser Ala Gly 
1               5                   10                  15      
Glu Lys Val Thr Met Arg Cys Lys Ser Ser Gln Ser Leu Leu Asn Ser 
            20                  25                  30          
Gly Met Arg Lys Ser Phe Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln 
        35                  40                  45              
Ser Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg Glu Ser Gly Val 
    50                  55                  60                  
Pro Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr 
65                  70                  75                  80  
Ile Ser Ser Val Gln Ala Glu Asp Leu Ala Val Tyr Tyr Cys Lys Gln 
                85                  90                  95      
Ser Tyr His Leu Phe Thr Phe Gly Ser Gly Thr Lys Leu Glu Ile Lys 
            100                 105                 110         



<210> 9
<211> 262
<212> PRT
<213> Artificial Sequence


<220> 
<223> antibody

<400> 9
Gln Ile Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Ala 
1               5                   10                  15      
Ser Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Tyr 
            20                  25                  30          
Tyr Ile Asn Trp Val Lys Leu Lys Pro Gly Gln Gly Leu Glu Trp Ile 
        35                  40                  45              
Gly Trp Ile Tyr Pro Gly Ser Gly Asn Thr Lys Tyr Asn Glu Lys Phe 
    50                  55                  60                  
Lys Gly Lys Ala Thr Leu Thr Ile Asp Thr Ser Ser Ser Thr Ala Tyr 
65                  70                  75                  80  
Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Thr Ala Val Tyr Phe Cys 
                85                  90                  95      
Val Arg Asp Ser Pro Phe Phe Asp Tyr Trp Gly Gln Gly Thr Thr Leu 
            100                 105                 110         
Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly 
        115                 120                 125             
Gly Gly Ser Asp Ile Val Leu Ser Gln Ser Pro Ser Ser Leu Ala Val 
    130                 135                 140                 
Ser Ala Gly Glu Lys Val Thr Met Arg Cys Lys Ser Ser Gln Ser Leu 
145                 150                 155                 160 
Leu Asn Ser Gly Met Arg Lys Ser Phe Leu Ala Trp Tyr Gln Gln Lys 
                165                 170                 175     
Pro Gly Gln Ser Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg Glu 
            180                 185                 190         
Ser Gly Val Pro Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe 
        195                 200                 205             
Thr Leu Thr Ile Ser Ser Val Gln Ala Glu Asp Leu Ala Val Tyr Tyr 
    210                 215                 220                 
Cys Lys Gln Ser Tyr His Leu Phe Thr Phe Gly Ser Gly Thr Lys Leu 
225                 230                 235                 240 
Glu Ile Lys Gly Ser Tyr Pro Tyr Asp Val Pro Asp Tyr Ala Gly Ser 
                245                 250                 255     
His His His His His His 
            260         

<210> 10
<211> 262
<212> PRT
<213> Artificial Sequence


<220> 
<223> humanized antibody

<400> 10
Gln Val Gln Leu Gln Gln Ser Gly Ala Glu Leu Val Lys Pro Gly Ala 
1               5                   10                  15      
Ser Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Tyr 
            20                  25                  30          
Tyr Ile Asn Trp Val Lys Leu Ala Pro Gly Gln Gly Leu Glu Trp Ile 
        35                  40                  45              
Gly Trp Ile Tyr Pro Gly Ser Gly Asn Thr Lys Tyr Asn Glu Lys Phe 
    50                  55                  60                  
Lys Gly Lys Ala Thr Leu Thr Ile Asp Thr Ser Ser Ser Thr Ala Tyr 
65                  70                  75                  80  
Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Thr Ala Val Tyr Phe Cys 
                85                  90                  95      
Val Arg Asp Ser Pro Phe Phe Asp Tyr Trp Gly Gln Gly Thr Leu Leu 
            100                 105                 110         
Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly 
        115                 120                 125             
Gly Gly Ser Asp Ile Val Leu Thr Gln Ser Pro Asp Ser Leu Ala Val 
    130                 135                 140                 
Ser Leu Gly Glu Arg Val Thr Met Asn Cys Lys Ser Ser Gln Ser Leu 
145                 150                 155                 160 
Leu Asn Ser Gly Met Arg Lys Ser Phe Leu Ala Trp Tyr Gln Gln Lys 
                165                 170                 175     
Pro Gly Gln Ser Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg Glu 
            180                 185                 190         
Ser Gly Val Pro Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe 
        195                 200                 205             
Thr Leu Thr Ile Ser Ser Val Gln Ala Glu Asp Val Ala Val Tyr Tyr 
    210                 215                 220                 
Cys Lys Gln Ser Tyr His Leu Phe Thr Phe Gly Ser Gly Thr Lys Leu 
225                 230                 235                 240 
Glu Ile Lys Gly Ser Tyr Pro Tyr Asp Val Pro Asp Tyr Ala Gly Ser 
                245                 250                 255     
His His His His His His 
            260         

